Market Closed -
Nasdaq
21:30:01 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
14.36
USD
|
-6.69%
|
|
-9.91%
|
+57.80%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
18,865
|
4,212
|
190.9
|
47.45
|
7.295
|
14.85
|
-
|
-
|
Enterprise Value (EV)
1 |
18,865
|
4,212
|
190.9
|
47.45
|
7.295
|
14.85
|
14.85
|
14.85
|
P/E ratio
|
-19.2
x
|
-3.07
x
|
-2.05
x
|
-1.14
x
|
-0.08
x
|
-15.8
x
|
-14.8
x
|
-13.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,115
x
|
629
x
|
35.4
x
|
2.63
x
|
3.79
x
|
-
|
-
|
-
|
EV / Revenue
|
1,115
x
|
629
x
|
35.4
x
|
2.63
x
|
3.79
x
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-2,689,073
x
|
-1,767,381
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,215
|
554
|
39
|
39.2
|
802
|
1,034
|
-
|
-
|
Reference price
2 |
15,523
|
7,603
|
4,896
|
1,210
|
9.100
|
14.36
|
14.36
|
14.36
|
Announcement Date
|
11/03/20
|
08/03/21
|
02/03/22
|
29/03/23
|
29/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
16.92
|
6.699
|
5.398
|
18.05
|
1.924
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.14
|
-47.29
|
-82.13
|
-37.44
|
-27.35
|
-33
|
-36
|
-39
|
Operating Margin
|
-95.39%
|
-705.99%
|
-1,521.56%
|
-207.41%
|
-1,421.57%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-15.72
|
-67.18
|
-84.54
|
-41.63
|
-31.53
|
-33
|
-36
|
-39
|
Net income
1 |
-16.07
|
-63.5
|
-84.38
|
-41.66
|
-31.54
|
-33
|
-36
|
-39
|
Net margin
|
-95.01%
|
-947.9%
|
-1,563.1%
|
-230.78%
|
-1,639.5%
|
-
|
-
|
-
|
EPS
2 |
-806.4
|
-2,477
|
-2,390
|
-1,063
|
-114.0
|
-0.9100
|
-0.9700
|
-1.030
|
Free Cash Flow
|
-
|
-
|
-71
|
-26.85
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-1,315.39%
|
-148.72%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/20
|
08/03/21
|
02/03/22
|
29/03/23
|
29/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
1.35
|
0.219
|
1.173
|
1.033
|
14.95
|
0.896
|
0.475
|
0.643
|
0.236
|
0.571
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.46
|
-17.96
|
-20.85
|
-11.83
|
4.095
|
-8.855
|
-9.267
|
-7.15
|
-3.75
|
-7.658
|
-4.7
|
-6.7
|
-12.8
|
-8.8
|
Operating Margin
|
-1,219.48%
|
-8,202.28%
|
-1,777.75%
|
-1,145.01%
|
27.39%
|
-988.28%
|
-1,950.95%
|
-1,111.98%
|
-1,588.98%
|
-1,341.16%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-17.46
|
-19.15
|
-22.04
|
-12.98
|
3.197
|
-9.804
|
-9.947
|
-8.186
|
-5.22
|
-8.177
|
-4.7
|
-6.7
|
-12.8
|
-8.8
|
Net income
1 |
-17.4
|
-19.2
|
-22.05
|
-12.99
|
3.192
|
-9.812
|
-9.955
|
-8.193
|
-5.228
|
-8.168
|
-4.7
|
-6.7
|
-12.8
|
-8.8
|
Net margin
|
-1,288.52%
|
-8,765.3%
|
-1,879.88%
|
-1,257.21%
|
21.35%
|
-1,095.09%
|
-2,095.79%
|
-1,274.18%
|
-2,215.25%
|
-1,430.47%
|
-
|
-
|
-
|
-
|
EPS
2 |
-489.6
|
-460.8
|
-576.0
|
-331.2
|
81.60
|
-249.6
|
-204.0
|
-141.6
|
-26.40
|
-113.0
|
-1.180
|
-0.1900
|
-0.3600
|
-0.2500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
02/03/22
|
05/05/22
|
04/08/22
|
07/11/22
|
29/03/23
|
04/05/23
|
03/08/23
|
09/11/23
|
29/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-71
|
-26.8
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.11
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
2.09%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/20
|
08/03/21
|
02/03/22
|
29/03/23
|
29/03/24
|
-
|
-
|
-
|
Last Close Price
14.36
USD Average target price
35
USD Spread / Average Target +143.73% Consensus |
1st Jan change
|
Capi.
|
---|
| +57.80% | 14.85M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +28.07% | 12.14B | | +0.17% | 12.15B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|